Cannabis Science (CBIS) today announced negotiations with several parties to make their anti-cancer Cannabis formulations available to the public (see full press release below). New interest from investors may spark a reversal and help CBIS break out of a 3 month downtrend.
May 24, 2010
COLORADO SPRINGS, Colo.–(BUSINESS WIRE)–Cannabis Science, Inc. (OTCBB: CBIS), a US biotech company developing pharmaceutical cannabis products, is pleased to announce negotiations with several commercialization groups to bring its anti-cancer cannabis formulations to the public as soon as possible. This collection of public data will be a major contribution to the body of evidence that will guide our Investigative New Drug Applications to the FDA for critical ailments such as cancer.
Cancer is our number one target based on our acquisition of physician documented positive treatment results. Beyond the well-known palliative options that cannabis provides for patients suffering from cancer and the side effects of the standard treatments, there has been a worldwide explosion of scientific studies demonstrating the ability of cannabinoids to kill cancer cells in animals and tissue culture. Additionally, patients have initiated personal experimentation in medical marijuana states. Currently, the Company, in collaboration with the Phoenix Tears Foundation (PhoenixTearsFoundation.com), is aware of multiple patients involved in a cannabis-based self-treatment regimen designed to cease cancer progression, improve quality of life through increased sleep and nutrition intake, and in a number of cases put patients in remission.
It is now clear that a standardized, well-profiled, and safe cannabis extract must be used for the treatment of this disease. Cannabis Science has been actively working with other organizations – in the US and abroad – to meet this need not only on the dispensary level, but also in pursuing FDA approval. Our short-term goal is to coordinate clinical partnerships and patient care with a standardized Cannabis Science product line in Colorado, and to gather data that supports the use of cannabis extracts for this indication. Cancer drugs tend to be hugely expensive. It is a multi-billion dollar market. However, it is not clear how the current market size could be extrapolated into any valuation of cannabis products, which would cost far less.
The Company is also developing some creative new national and international educational programs about Cannabis Science for a variety of media. The focus will be on patient interactions, successful self-medication, pharmaceutical grade cannabis product development, quality control standardizations, successful anti-cancer cannabis treatments, as well as patient data retention nationally and internationally.
Basic due diligence:
Cannabis Science, Inc.
2422 S Trenton Way
Denver, CO 80231
Cannabis Science, Inc. engages in the development, production, and commercialization of phytocannabinoid-based pharmaceutical products. It primarily focuses on developing blood pressure and cancer medications, as well as HIV and bird flu medications. Cannabis Science, Inc. is based in Colorado Springs, Colorado
Transfer Agent: Routh Stock Transfer Inc.
6060 North Dallas Parkway
Plano, Texas 75024
Authorized Preferred Shares 1,000,000
Issued Preferred Shares 1,000,000
Authorized Common Shares 250,000,000
Issued Common Shares 116,170,574